HARMONY BIOSCIENCES HOLDINGS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.18 USD | +3.01% |
|
+7.36% | -3.84% |
| 04-30 | Harmony Biosciences Acquires Epygenix Therapeutics; Shares Rise | MT |
| 04-30 | Transcript : Harmony Biosciences Holdings, Inc., Q1 2024 Earnings Call, Apr 30, 2024 |
Chart calendar Harmony Biosciences Holdings, Inc.
b267eb94ca903405d43.Mrh5n0yQux6oQnrOk0kY9xZ-HJXWXhKnvRFdKRIhwPw.fZUr9jXA2EfFJEOW9XxfpiQzL9auMWqViGAxGiB5q4x30iboGOiDc8IUMw~b36f18c72db4e66d5ef1b1f58a90cd31
Upcoming events on Harmony Biosciences Holdings, Inc.
Past events on Harmony Biosciences Holdings, Inc.
| 30/04/2024 13:30 | Q1 2024 Earnings Call |
| 29/04/2024 | Q1 2024 Earnings Release Pre-market |
| 08/04/2024 14:30 | Needham Healthcare Conference |
| 12/03/2024 19:35 | Barclays Global Healthcare Conference |
| 11/03/2024 16:40 | Leerink Partners Global Biopharma Conference |
| 22/02/2024 13:30 | Q4 2023 Earnings Call |
| 22/02/2024 12:30 | Q4 2023 Earnings Release |
| 11/01/2024 01:15 | JPMorgan Healthcare Conference |
| 05/12/2023 22:00 | American College of Neuropsychopharmacology Meeting |
| 30/11/2023 14:00 | Piper Sandler Healthcare Conference - Fireside Chat |
| 31/10/2023 12:30 | Q3 2023 Earnings Call |
| 31/10/2023 11:30 | Q3 2023 Earnings Release |
| 13/10/2023 13:30 | INTUNE Phase 3 Study Results Call |
| 27/09/2023 15:20 | Cantor Global Healthcare Conference |
| 14/08/2023 13:30 | Acquisition of Zynerba Pharmaceuticals, Inc by Harmony Biosciences Holdings, Inc Call |
| 01/08/2023 13:30 | Q2 2023 Earnings Call |
| 01/08/2023 12:30 | Q2 2023 Earnings Release |
| 13/06/2023 22:00 | Goldman Sachs Global Healthcare Conference |
| 07/06/2023 21:30 | Associated Professional Sleep Societies Meeting |
| 06/06/2023 22:00 | Associated Professional Sleep Societies Meeting - Poster No - 510 |
Annual results
| Fiscal Period | December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 160 155 2.86% | 305 304 0.54% | 438 437 0.23% | 582 582 0.03% | 712 |
|
EBITDA Million USD | Released Forecast Spread | 27,3 26,4 3.34% | 106 97,2 9.43% | 144 161 -11% | 216 241 -10.22% | 207 |
|
EBIT Million USD | Released Forecast Spread | 17,0 21,2 -19.93% | 87,5 86,6 1.02% | 120 118 2.26% | 192 199 -3.72% | 200 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -36,9 -30,5 -21.33% | 37,4 39,6 -5.4% | 105 102 3.07% | 173 174 -0.51% | 184 |
|
Net income Million USD | Released Forecast Spread | -63,8 -33,5 -90.88% | 34,6 37,2 -6.95% | 181 168 7.83% | 129 139 -6.98% | 148 |
|
EPS USD | Released Forecast Spread | -2,48 -0,58 -327.59% | 0,58 0,63 -8.18% | 2,97 2,74 8.3% | 2,13 2,17 -1.84% | 2,44 |
| Announcement Date | 25/03/21 | 28/02/22 | 21/02/23 | 22/02/24 | - |
Quarterly results
| Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 85,3 88,6 -3.66% | 107 101 6.23% | 117 114 3.23% | 128 127 0.76% | 119 116 2.52% | 134 142 -5.51% | 160 149 7.85% | 168 168 0.09% | 155 154 0.34% | 174 | 187 | 197 | 182 | 205 |
|
EBITDA Million USD | Released Forecast Spread | 53,0 41,6 27.32% | |||||||||||||
|
EBIT Million USD | Released Forecast Spread | 27,6 23,4 17.91% | 33,1 33,9 -2.2% | 11,9 18,8 -36.55% | 47,6 45,0 5.85% | 40,4 39,4 2.72% | 46,9 55,3 -15.14% | 64,5 57,2 12.71% | 40,2 44,8 -10.33% | 52,0 48,9 6.48% | 21,0 | 57,9 | 58,5 | 62,2 | 70,6 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 23,4 18,0 29.82% | 29,2 29,1 0.29% | 7,97 10,7 -25.33% | 44,1 39,7 11.16% | 37,8 37,0 2.21% | 44,1 50,1 -12.05% | 51,8 52,9 -2.03% | 39,7 34,1 16.32% | 51,8 46,8 10.67% | 22,7 | 54,2 | 53,7 | 60,0 | 68,5 |
|
Net income Million USD | Released Forecast Spread | 21,5 17,2 25.26% | 23,5 27,0 -12.99% | 87,8 5,80 1414.55% | 48,5 33,5 44.68% | 29,5 27,9 5.66% | 34,3 39,1 -12.28% | 38,5 41,1 -6.41% | 26,6 28,4 -6.43% | 38,3 35,2 8.79% | 17,0 | 40,8 | 40,4 | 45,5 | 52,0 |
|
EPS USD | Released Forecast Spread | 0,35 0,29 19.51% | 0,39 0,45 -13.33% | 1,44 0,10 1376.92% | 0,79 0,57 38.29% | 0,48 0,46 3.7% | 0,56 0,61 -8.01% | 0,63 0,65 -3.08% | 0,45 0,48 -6.01% | 0,67 0,60 10.87% | 0,24 | 0,73 | 0,74 | 0,75 | 0,85 |
| Announcement Date | 03/05/22 | 02/08/22 | 01/11/22 | 21/02/23 | 02/05/23 | 01/08/23 | 31/10/23 | 22/02/24 | 30/04/24 | - | - | - | - | - |
More events
Past sector events for Harmony Biosciences Holdings, Inc.
| Today 12:30 | ORGANON & CO.: Q1 2024 Earnings Release |
| Today 06:30 | NOVO NORDISK A/S: Q1 2024 Earnings Release |
| Today | BAUSCH HEALTH COMPANIES INC.: Q1 2024 Earnings Release |
| Today | AMGEN INC.: Q1 2024 Earnings Release |
| 01/05/2024 21:05 | CORCEPT THERAPEUTICS INCORPORATED: Q1 2024 Earnings Release |
| 01/05/2024 21:05 | JAZZ PHARMACEUTICALS PLC: Q1 2024 Earnings Release |
| 01/05/2024 11:45 | PFIZER, INC.: Q1 2024 Earnings Release |
| 01/05/2024 08:00 | HALEON PLC: Q1 2024 Sales and Revenue Release - Trading Statement |
| 01/05/2024 07:00 | GSK PLC: Q1 2024 Earnings Release |
| 30/04/2024 | INNOVIVA, INC.: Q1 2024 Earnings Release (Projected) |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- HRMY Stock
- Calendar Harmony Biosciences Holdings, Inc.
